Get tips on navigating low-code platforms and hear from Gilead Sciences VP on her work on HIV, hepatitis, and COVID-19.
On-Demand White Paper and Podcast
How to Navigate the Challenges of Working with Low-Code Platforms
This complimentary white paper offers helpful guidance for how to mitigate the hidden risks low-code platforms present. It also presents a list of recommendations for addressing these challenges.
Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talkes about the pharma company's work in HIV and hepatitis and how her personal background informed her team's work in developing a COVID-19 treatment.
No comments